OPC1
phase 1drug program · high · Mon Jun 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Replace or support absent or dysfunctional cells after traumatic spinal cord injury, with the goal of improving quality of life and restoring or augmenting functional activity.
Cell therapy administered to the spinal cord; studies include dose escalation, long-term follow-up, and evaluation of a delivery device for administering LCTOPC1.
DOSED clinical study evaluating the safety and utility of a novel delivery device for LCTOPC1 in spinal cord injury participants, published 2025-06-30.
Prior and ongoing public records describe safety-focused clinical studies and long-term follow-up of recipients of AST-OPC1/GRNOPC1 cells; no efficacy results are provided in the supplied material.